Abstract:1862 Objectives: To prepare 99mTc-IT-rituximab, a novel sentinel lymphoscintigraphy agent, and evaluate its ability in detecting the sentinel lymph node. Methods: Rituximab was radiolabeled with 99mTc via 2-iminothiolane (2-IT). The resulting 99mTc-IT-Rituximab were analysed for number of free sulfhydryl groups. The integrity of IT-rituximab was evaluated by SDS-PAGE, ELISA, which could evaluated the optimal modifying conditions. The immunological biology of 99mTc-IT-rituximab was evaluated by flow-cytometric analysis (FCA). Comparing the radiocolloid, 99mTc-IT-Rituximab was evaluated with biological distribution results, and image of sentinel lymph node (SLN) was obtained at 30min-24h postinjection with 99mTc-IT-rituximab in mice. The influenced factors on the imaging by the injecting dosage and volume were also observed in mice. Results: Optimal conditions for modifying Rituximab involved a 10:1 molar ratio of 2-IT : protein in 4°C, the number of apparent thiol produced were 2.1 per IT-Rituximab. 99mTc-IT-rituximabwas stable for 24 h at 37°C in human serum. 99mTc-IT-rituximab was proved to have the similar immunological character with rituximab by SDS-PAGE, ELISA and FCA. Its binding rate of B lymphoma cell line Raji cell is 69.4%. After subcutaneous injection into the foot pads of mice, 99mTc-IT-rituximab showed high accumulationn the knee. The mean %ID of the popliteal lymph node at 1, 4, 8, and 24 h was (2.33±0.13)%, (2.72±0.12)%, (3.71±0.28)%, and (4.49±0.43)%, respectively. The mean %ID of NSLN was less than 0.2% at each time point. With increasing the injected dose or volume the %ID of SLN would decrease, while the %ID of NSLN would increase gradually. 99mTc-IT-rituximab exhibited faster injection site clearance than did 99mTc-SC and 99mTc-DX, %ID of the rear paws was (22.14±2.08)% at 24 h after administration. In mice, the results of dynamic SLN mapping show that SLN could be seen within a wide range from 30 min to 24 h postinjection. The higher order nodes had not been seen all the time. 99mTc-IT-rituximab was mainly excreted by kidney, other tissues exhibited less than 1 percent of the injected dose at all time points. For radiocolloid, the higher echelon node extraction was significantly higher. The 99mTc-SC and 99mTc-DX %ID of the second-order node was (4.93±0.37) % and (8.54±0.78) % at 2 h. The uptake of second echelon for 99mTc-HSA was also higher than 99mTc-IT-rituximab. Conclusions: 99mTc-IT-Rituximab, as a tracer to mapping SLN, could predict the status of SLNs reliably.

The study of 99mTc-sulphur colloidal particles' properties and internal mammary sentinel nodes lymphoscintigraphy

Factors affecting 99Tcm-sulphur colloid internal mammary sentinel nodes lymphoscintigraphy

Sentinel Lymph Node Biopsy in Breast Cancer Patients after Overnight Migration of Radiolabelled Sulphur Colloid

Mammary sentinel lymphoscintigraphy in breast cancer

Sentinel Lymph Node Imaging with a Novel Radiotracer: Preparation of 99Tcm-It-rituximab and Experimental Study

The effect of different injection locations of 99mTc-sulfur colloid for sentinel lymph node detection in breast cancer?

Does the Preparation and Utilization of 99mTc-Sulfur Colloid Affect the Outcomes of Breast Lymphoscintigraphy?

The Study on the Potential Clinical Value of Sentinel Lymphoscintigraphy in the Radiation Target Volume Design of Internal Mammary Nodes

Development and animal study of sentinel lymph node imaging with a novel radiotracer

Comparison of [99mTc]Tc-tilmanocept with [99mTc]Tc-sulphur colloids and [99mTc]Tc-albumin colloids for sentinel lymph node detection in patients with cutaneous malignancies of the head

The preparation and localization study of a novel sentinel lymphoscintigraphy agent 99Tcm-IT-Rituximab

Sentinel Lymph Node Mapping Using Near-infrared Fluorescence

99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study

Intra-operative Radionuclide Lymphatic Mapping in Sentinel Lymph Node Biopsy of Breast Cancer

Compared the Efficacy of Mitoxantrone Hydrochloride Injection for Tracing with Radionuclide in Sentinel Lymph Node Biopsy of Breast Cancer

Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient]

Comparison of 99Tcm-rituximab planar and SPECT/CT lymphoscintigraphy for sentinel lymph nodes of breast cancer

[Preliminary Study of New Imaging Agent, 99Mtc-Rituximab, for Sentinel Lymph Node Biopsy of Primary Breast Cancer].

[Lymphoscintigraphy in Sentinel Lymph Node Biopsy of Breast Cancer].

Experimental Study of Biological Property and Safety Limitation of Sentinel Lymph Node Imaging Agent 99Tcm-Rituximab

Sentinel Lymph Node Biopsy with a Novel Sentinel Lymphoscintigraphy Agent 99Mtc-Rituximab for Breast Cancer